Novocure’s Optune Pax Gains CE Mark for Locally Advanced Pancreatic Cancer
Event summary
- Novocure’s Optune Pax received CE Mark for treating locally advanced pancreatic cancer in June 2026.
- Phase 3 PANOVA-3 trial showed a statistically significant 2.0-month improvement in median overall survival (mOS) when combined with gemcitabine and nab-paclitaxel (gem/nab-pac).
- Optune Pax also extended time to pain progression by 6.1 months compared to gem/nab-pac alone.
- The device was well-tolerated, with no new safety signals observed.
The big picture
Novocure’s CE Mark for Optune Pax addresses a critical unmet need in treating locally advanced pancreatic cancer, a disease with rising incidence and low survival rates. The approval follows positive Phase 3 trial results demonstrating improved overall survival and delayed pain progression, positioning Novocure to expand its footprint in the oncology market. The strategic significance lies in the potential for TTFields therapy to complement existing treatments across multiple solid tumor types.
What we're watching
- Market Expansion
- The pace at which Novocure can secure national agency approvals and launch Optune Pax in key European markets.
- Clinical Versatility
- Whether the multi-mechanistic actions of Tumor Treating Fields (TTFields) will enhance effects across other solid tumor types when combined with existing therapies.
- Competitive Positioning
- How Novocure’s strategic focus on pancreatic cancer and other aggressive cancers positions it against competitors in the oncology space.
Related topics